

CURRICULUM VITAE

PERSONAL INFORMATION

Name : Meral (Özgü) Beksac
Gender : Female
Date and place of birth : October 25, 1956-İzmir, Turkey
Marital status : Married with Two children
Nationality : Turkish
Language : English, German, Swedish
Institution : Ankara University Faculty Of Medicine Cebeci Hospital
Hematology Department 06590 Cebeci/Ankara
Medical Licence Number : 29946
Website : www.multipmiyelom.com ; www.kokhucrebagisla.com;
www.tkitv.org.tr ; www.kordonkanibagisla.com
E-mail : beksac@medicine.ankara.edu.tr
Phone : +90 312 5957443 (office)
+90 5957099(secretary) +905958596(clinical trial coordinators)
Fax : +90 312 309 58 69 or +90 312 235 57 63

EDUCATION:

September 1991 :Degree in Hematology
Ankara University, School of Medicine Ankara, Turkey.
Thesis: Association of Human Histocompatibility Antigens with Hematological disorders:
Aplastic anemia and Leukemias
December 1986 :Completed Residency in the Department of Internal Medicine,
Hacettepe School of Medicine, Ankara, Turkey.
Thesis: Cytotoxicity of monoclonal antibodies against individually immunophenotyped
human leukemic myeloblasts.
June 1980 :M.D., School of Medicine
Hacettepe University, Ankara, Turkey.
June 1974 :High School Degree, Ankara, Turkey.

ACADEMIC TITLES AND PRIZES:

2004- : Member of Turkish Academy of Sciences

1995-2003: Associate member Turkish Academy of Sciences

1993 - :Professor in Hematology. Ankara University

1987 :Associate Professor of Internal Medicine, Hacettepe University (affiliated to a State Hospital for Postgraduate Medicine, Ankara)

1986 :Turkish Cancer Society Kaymakçalan award for young scientists.

1973 : Scientific and Technical Research Council of Turkey project contest, third prize.

EXPERIENCE:

2001- ongoing: past chairman and currently member of the Turkish Myeloma Study Group

2013-2016: European Hematology Association Scientific Program Committee, member

August 2006 – until today: Director of the Ankara University Cord Blood Bank

2001-today: director of the Ankara University Unrelated Donor and Cord Blood Registry (TRAN and T1CB)

August 2006: visiting scientist Royal Marsden Hospital / Institute for Cancer Research Sutton Surrey, Division of Hematology (Chair: Prof.Dr. Gareth Morgan)

July 2005- august 2005:Visiting scientist at the Bone Marrow Transplantation Center and Molecular Imaging Lab at Stanford University Medical Hospital, San Francisco, USA (Chair: Prof.Dr.Robert Negrin, Assoc.Prof.Dr.Christopher Contag)

Dec 2001- 2004; 2011-: President of the Turkish Foundation for Bone Marrow Transplantation

Sept 1996-October 2001 : Elected member of the Executive Committee of Turkish Society of Hematology

Nov 1997-Nov 2000: Elected member representing professors at the Council of the School of Medicine, Ankara University

July 1993-until now: Professor at the Department of Hematology, Ankara University School of Medicine, İbn-i Sina Hospital, Ankara, Turkey.

July 2001 – Aug 2001: Visiting physician at the Bone Marrow Transplantation Center and Histocompatibility Lab at Stanford University Medical Hospital, San Francisco, USA (Chair: Assoc.Prof.Dr.Robert Negrin and Prof.Dr.Carl Grumet)

July – Aug 2000: visiting professor at the Myeloma & Bone Metastasis Program, Hematology-Oncology, Cedars Sinai Medical Center, UCLA, LA (chair: Prof. JR Berenson)

July – Aug 1999: visiting fellow at the Comprehensive Cancer Center, New York Medical College, NY (chair: Prof. P Wiernik)

July – Aug 1998 : visiting physician at the Division of Medical Oncology VA Medical Center , UCLA , LA (chair: Prof. JR Berenson)

July – Aug 1997 : visiting scientist at Harvard Medical School, Department of Pharmacology and Core Flow Cytometry Facility at Dana Farber Cancer Institute, Boston, MA.

Jan 6 1995 - Jan 6 1998: Head of the Department of Hematology Ankara University School of Medicine, İbn-i Sina Hospital, Ankara, Turkey.

May 1991: observer at the Department of Hematology, University College Hospital, London (chair: Prof.A.Goldstone) and Royal Marsden Hospital (chair: Prof. D.Catovsky)

Jan 6 1989 - July 1993: Assoc Prof. at the Department of Hematology, Ankara University School of Medicine , İbn-i Sina Hospital, Ankara, Turkey.

Dec 27 1985 - Apr 1988: compulsory two years of work to the Turkish Ministry of Health, at the hospital for Post-graduate Medicine, Division of Hematology-Immunology, Ankara, Turkey

March 9 1983 - May 30 1984: Visiting scientist at the Department of Hematology, Karolinska Hospital, Stockholm. Sweden (on leave of absence from Hacettepe University).

July 1,1977 – Sept 10 1977: Elective study at the Department of Internal Medicine, Rudolf Krehl Klinik, University of Heildelberg, Germany.

July 15 1980 - Feb 28 1983 and June 1 1984 - Dec12,1985 Resident at the Department of Internal Medicine, Hacettepe Faculty of Medicine, Ankara, Turkey.

Jan 1979 - June 1980: Part time voluntary research technician at the Reproductive Endocrinology Unit, Hacettepe University, Ankara, Turkey

Nov 1978 – Dec 1978 : Part time resarch technician at the Immunology Lab (Tissue Typing) Hacettepe Children's Hospital , Ankara, Turkey.

MEMBERSHIPS:

1. Turkish Academy of Sciences (since 1995-)
2. International Myeloma Foundation (International Scientific Advisory Board member since 1999)
3. European Myeloma Network member (since 2001-)
4. World Marrow Donors Association (WMDA, 2000, 2007-)
5. European Blood and Marrow Transplantation Group (EBMT,since 1991)
6. International Bone Marrow Transplantation Registry (CIBMTR, since 1990)
7. International Society of Hematology (ISH, 1991-2010)
8. European Association for Hematology
9. European Organization for Cancer Research and Treatment-Leukemia Cooperation Group (EORTC-LCG) (Active Member 1991- 2010)
10. Turkish Society of Hematology (1989-)
11. Turkish Bone Marrow Transplantation Foundation (founding member and president)
12. American Society of Hematology (ASH, since 1995-)
13. European Federation of Immunogenetics (EFI, since 2000-)
14. American Society for Blood and Marrow Transplantation (ASBMT, since 2008-)
15. International Society of Multiple Myeloma (ISMM, since 2009 -)

EDITORIAL BOARD :

1. Bone Marrow Transplantation (past)
2. Advances in Hematology

BOOKS:

Molecular methods in stem cell transplantation April 2007 first edition; second edition 2014(Humana Press); Editor: Meral Beksac Chapters from the book:

- Sequence Specific Primed PCR (PCR-SSP) Typing of HLA Class I and Class II Alleles (K. Dalva, M. Beksac, Ankara, Turkey).
- HLA typing with Sequence Specific Oligonucleotide Primed PCR(PCR-SSOP) and use of the Luminex™ technology (K. Dalva, M. Beksac, Ankara, Turkey)
- Application of Immunohistochemistry and Fluorescent In Situ Hybridization for detection of Donor Type Cells: (I. Kuzu, M. Beksac, Ankara,Turkey)

A Quick Reflection on the Fast Progress: editor Roman Hajek 2013:

- Induction Therapy in Multiple Myeloma (S.M.Bakanay, M.Beksac, Ankara, Turkey)

PUBLICATIONS:

1. Erodogan M, Inal A, **Ozgu M**, Beksac MS, Ergurbuz I. Effect of oral contraceptive (ethinyl estradiol and d-norgestrel) on serum prolactin-oestradiol and progesterone levels Acta Reprod Turc. 1980 Jan;1(3):85-91.
2. **Beksaç M.S.**, Kişnişçi H.A., Çakar A.N. and **Beksaç M.**: The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. Int. J. of Fertility 28: 219-224, 1983.
3. **Beksaç M.S.**, **Beksaç M.**, Kişnişçi H.A. and Kökçü A.: Stress induced release of cortisol and prolactin during dilatation and curettage under general and local anesthesia. Neuropsychobiology 11: 227-228, 1984.
4. **Beksaç M.**, Porwit Ksiazek A., Hast R., Biberfeld P. and Reizenstein P.: Cytotoxicity of monoclonal antibodies against individually immunophenotyped human leukemic cells. Cancer Immunology Immunotherapy 19: 231-236, 1985.
5. **Beksaç M.**, Peterson C. and Reizenstein P.: Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients. Cancer Chemotherapy and Pharmacology 15. 72-75, 1985.
6. Reizenstein P., **Beksaç M.**, Biberfeld P., Christensson B., Lagerlöf B., Lauren L., Öst A. and Porwit Ksiazek A. Leukemic myeloblasts expressing lymphoid markers. Acta Hematologica 74: 148-150, 1985.
7. Hast R., **Beksaç M.**, Axdorf S., Sjögren A.M., Öst A. and Reizenstein P.: Effect of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. Medical Oncology and Tumor Pharmacotherapy 3: 35-38, 1986.
8. Ösby E., **Beksaç M.**, and Reizenstein P.: Alternating combination therapy does not delay development of refractoriness in myeloma. Anticancer Research 6:1145-1148, 1986.

9. **Beksaç M**, Kansu E, Kars A, İbrahimoglu Z, Fırat D: A rapid drug sensitivity assay for neoplastic cells. *Med Oncol Tumour Pharmacother.*5:253-257 , 1988
10. **Beksaç M.**, Akan H., Koç H., İlhan O., Ertürk P., Güneylı A., İkizunal Y., Şardaş O.S.: P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing protocols. *Medical Oncology and Tumor Pharmacotherapy* 9 (2); 101-105, 1992.
11. Karakaya A., Tuncel N., Yücesoy B., Akın M., Çuhruk H., Şardaş O.S., **Beksaç M.**: The effects of volatile anesthetic agents on human immune system function via occupational exposure. *Immunopharm. Immunotoxicol* 14 (182): 251-259, 1992.
12. **Beksaç M.**, Dalva K., Gönenç F., Dalva I., Gariboğlu S., Batur N., Çetin S.: Soluble CD23 and Interleukin 2 receptor levels in renal allograft recipients. *Transplantation Proceedings* 25(2) (April) : 3043-3045, 1993.
13. **Beksaç M.**, Ertürk Ş., Akan H., Koç H., İlhan O.: The clinical correlations of serum tumor necrosis factor alpha in acute leukemias. A predictor of response and relapse? *Leukemia* 7(11): 1773-1776, 1993.
14. Akan H., Koç H., **Beksaç M.**, İlhan O., Gürman G., Aydoğdu İ., Şardaş O.S.: Case report : complications of bone marrow transplantation ; a long way to run .*Libri Oncol.* 22(3) : 219-221 ,1993.
15. Akan H., **Beksaç M.**, Aydoğdu İ., Koç H., İlhan O., Özcan M.: Peripheral T cell receptors α, β and γ, δ in Hodgkin's Lymphoma. *Br. J. Haematol.* 87:544-547, 1994
16. İlhan O, Uysal A, Aydoğdu İ, **Beksaç M**, Akan H, Koç H: Mitoxantrone and cytosine arabinoside in previously untreated patients with acute non-lymphocytic leukemia. *Haematologica* 27(2):93-97, 1996
17. Arslan Ö, Akan H, Koç H, **Beksaç M**, İlhan O, Özcan M, Yalçın S, Gürman G, Konuk N, Uysal A Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen. *Bone Marrow Transplantation* 18:261-264, 1996
18. İlhan O, Koç H, Akan H, Gürman G, Arslan Ö, Özcan M, Arıkan N, Sencer H, Konuk N, Uysal A, **Beksaç M**. Hemorrhagic cystitis as a complication of bone marrow transplantation. *J of Chemotherapy* 9:56-61, 1996
19. Akan H, Koç H, Arslan Ö, **Beksaç M**, İlhan O, Gürman G, Özcan M. Febrile neutropenia in a bone marrow transplantation center. *Int J of Antimicrob Agents* 8:127-130 1997

20. İlhan O, Akan H, Koç H, Gürman G, Arslan Ö, Özcan M, Erdi H, Erdem C, Konuk N, Uysal A, **Beksaç M**. Incidence of graft versus host disease in allogeneic bone marrow transplantation in a single center study from Turkey. *Hematol Cell Ther* 39:133-36, 1997
21. **Beksaç M**, Beksaç MS, Tipi VB, Duru HA, Karakaş MÜ, Çakar AN. An artificial intelligent diagnostic system on differential recognition of hematopoietic cells from microscopic images. *Cytometry (Communications in clinical cytometry)* 30:145-150, 1997.
22. Üstün C, Koç H, Karayalçın S, Akyol G, Gürman G, İlhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, **Beksaç M**. Hepatitis B virus infection in allogeneic bone marrow transplantation. *Bone Marrow Transplant* 20, 289-196, 1997
23. Koç H, Arslan Ö, Gürman G, Akan H, Özcan M, İlhan O, Aydoğdu İ, Arat M, **Beksaç M**, Konuk N, Uysal A. The use of high dose chemotherapy plus granulocyte colony stimulating factor for the salvage of refractory or relapsed malignant lymphoma patients without stem cell support. *Acta Haematol* 98(3):136-139 1997
24. Koç H, Gürman G, Arslan Ö, Özcan M, Akan H, İlhan O, Konuk N, **Beksaç M**, Uysal A. Allogeneic peripheral blood stem cell transplantation. Is there an increased risk of GVHD in leukemia patients. *J of Chemother* 9(5):371-376 1997
25. İlhan O, **Beksaç M**, Arslan Ö, Özcan M, Koç H, Akan H. HLA DR2 a predictive marker in response to cyclosporine therapy in aplastic anemia. *Int J Hematol* 66:291-295, 1997
26. Üstün C, Karavelioğlu D, İlhan O, Aydınтуğ O, **Beksaç M**. A case report of a patient who has pure red cell aplasia and rheumatoid arthritis *Int J Hematol* 66:505-512, 1997.
27. Arslan Ö, Gürman G, Dilek İ, Özcan M, Koç H, İlhan O, Akan H, Konuk N, Uysal A, **Beksaç M**. Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey and review of the literature. *Hematologia* .29(2):133-7,1998.
28. Dilek İ, Koç H, Demirer T, Anadolu R, Üstün C, **Beksaç M**, Erdi H, Özcan M, Akan H. Acquired ichthyosis (superimposed upon chronic graft-versus-host disease) following an allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia "a case report" *Bone Marrow Transplant* .21(11):1159-61,1998
29. **Beksaç M**, Arslan Ö, Koç H, Akan H, İlhan O, Arat M, Özcan M, Gürman G, Konuk N, Uysal. Randomized unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia. *Medical Oncol* .15:183 -190, 1998
30. Arslan Ö, Üstün C, Arat M, Çelebi H, Akan H, **Beksaç M**, İlhan O, Gürman G, Özcan M, Konuk N, Uysal A, Koç H. .Allogeneic peripheral blood stem cell transplantation in acute nonlymphoblastic leukemia. *Hematol.Oncol* .16(4):155-62,1998.
31. Üstün C, Arslan Ö, **Beksaç M**, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O, Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek İ, Çelebi H, Coşkun HŞ. A retrospective

comparison of allogeneic peripheral stem cell and bone marrow transplantation .Results from a single center, a focus on the incidence of GVHD and relapse. Biol Blood Marrow Transplant. 5(1):28-35, 1999.

32. Aydođdu İ, İlhan O, **Beksaç M**, Koç H, Akan H, Konuk N, Uysal A..Serum erythropoetin levels in patients with leukemia on cytostatic treatment. Hematologia (Budap) 29(2):133-7,1998

33. Miniero R, Rocha V, Saracco P , Locatelli F , Brichard B, Nagler A, Roberts I, Yaniv I , **Beksac M**, Bernaudin F , Gluckman E on behalf of Eurocord.Cord blood transplantation in hemoglobinopathies. Bone Marrow Transpl 22 (Suppl 1): S78-S79 , 1998

34. Arslan Ö, Üstün C, Arat M, Çelebi H, Akan H, **Beksaç M**, İlhan O, Gürman G, Özcan M, Konuk N, Uysal A, Koç H. .Allogeneic peripheral blood stem cell transplantation in acute nonlymphoblastic leukemia. Hematol.Oncol.16(4):155-62, 1998

35. Üstün C, İdilman R, Gürman G, Özcan M, Akyol G, Akan H, İlhan O, **Beksaç M**, Uysal A, Konuk N, Karayalcın S, Poyraz A, Van Thiel D, Koç H..Hematopoietic stem cell transplantation from non-replicative hepatitisB virus carriers is safe.J Hepatol.31:202-209,1999.

36. Üstün C, Özcan M, Gürman G, Çakır M, Ereku S, Akyol G, Arat M, Çelebi H, İdilman R, Akan H, İlhan O, **Beksaç M**, Koç H. Differences in liver pathology and clinical outcome between two patients with hepatitis B virus and graft versus host disease. Pathol Oncol Res. 5(3): 229-32,1999.

37. Nergizođlu G, Keven K, Ateş K, Üstün C, Tolunay Ö, **Beksaç M**, Karatan O, Ertuğ AE.Chronic graft versus host disease complicated by membranous glomerulonephritis. Nephrol Dial Transplant 14(10):2461-3,1999.

38. İlhan O, Arslan Ö, Arat M, **Beksaç M**, Akan H, Özcan M, Gürman G, Konuk N, Uysal A, Koç H.The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci. 20(1):69-71,1999.

39. **Beksaç M**, Arat M, Akan H, İlhan O, Koç H, Özcan M. Circulating CD44 and ICAM-1 levels in patients with low grade NHL and CLL responsive or nonresponsive to interferon-alpha.Cancer 89(7):1474-1481,2000.

40. Arslan Ö, Akan H, Arat M, Dalva K, Özcan M, Gürman G, İlhan O, Konuk N, **Beksaç M**, Uysal A, Koç H. Soluble adhesion molecules (s ICAM-1, l-selectin, e-selectin, sCD44) in healthy alogeneic peripheral stem cell donors primed with recombinant G-CSF. Cytotherapy 2(4): 259-265,2000.

41. Arslan Ö, Coşkun HS, Arat M, Çelebi H, Özcan M, Gürman G, Üstün C, Demirer T, Akan H, İlhan O, Konuk N, **Beksaç M**, Uysal A, Koç H. Allogeneic peripheral blood stem cell transplantation for standard risk leukemias: Four years experience of Ibni Sina Hospital .Bone Marrow Transplant 25: 1229-1232, 2000

42. Akan H, Güven N, Aydođdu I, Arat M, **Beksac M**, Dalva K. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. *Acta Haematol* 103: 152-156, 2000.
43. Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M, Parker K, **Beksac M**, Belson D, Moss JJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR. Human herpes virus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma. *Clin Cancer Res.* 6(11): 4226-33, 2000.
44. **Beksac M**, Ma M, Akyerli C, Der Danielian M, Zhang L, Liu J, Arat M, Konuk N, Koc H, Özçelik T, Vescio H, Berenson JR. Frequent demonstration of Human herpes Virus 8 in bone marrow biopsy samples from Turkish patients with multiple myeloma. *Leukemia* ;15(8):1268-73. 2001
45. Sonneveld P, S. Suci, Weijermans P, **Beksac M**, Neuwirtova R, Solbu, Lokhorst H, van der Lelie, Dohner H, Gerhartz H, Segeren CM, Willemze R, Löwenberg B. Cyclosporin A combined with vincristine, doxorubicin, and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). *Br J Haem.* 115: 895-902, 2001.
46. G. Ongun, Halıcı U, Leblebiciođlu K, Atalay V, **Beksac M**, Beksac S. Automated colour detection in blood cell images by an efficient snake algorithm. *Nonlinear analysis: Series B-Applications.* 47: 5839-5847, 2001.
47. Gurman G, Dilek I, Arslan O, Arat M, **Beksac M**, İlhan O, Özcan M, Akan H, Dalva K, Konuk N, Uysal A, Koç H. The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. *Transfus Apheresis Sci.* 2001 Feb;24(1):23-8.
48. Arat M, Arslan O, **Beksac M**, Keven K, Nergizoglu G, Erturk S. Hematopoietic cell transplantation-related nephropathy (letter). *Am J Kidney Dis.* 38(1):218-9, 2001.
49. Özcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, İlhan O, **Beksac M**, Gurman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koc H. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 27(5):499-505, 2001.
50. Gurman G, Celebi H, Ustun C, Arat M, İlhan O, Özcan M, Arslan O, Uysal A, Akan H, **Beksac M**, Konuk N, Koc H. Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia. *Ther Apher.* Feb;5(1):54-7, 2001.
51. Ustun C; **Beksac M**; Dalva K; Koc H; Konuk N; İlhan O; Özcan M; Topcuoglu P; Sertkaya D; Hayran M. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves

complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia *Med Oncol* 19(1): 59-67 . 2002.

52. Schmitz N, **Beksac M.**, Hasenclever D.,Bacigalupo A., Ruutu T., Nagler A., Gluckman E.,Russell N.,Apperley J.F., Gorin N.C.,Szer J.,Bradstock K.,Buzyn A.,Clark P.,Borkett K.Gratwohl A. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. *Blood* 100(3):761-767,2002.

53. **Beksac M.** et al. The role of pretransplant Interferon –alpha treatment on the outcome of stem cell transplantation from related donors in chronic myelogenous leukemia. *Bone Marrow Transpl* 31 (10): 897-904 ,2003.

54. Kutlay S, **Beksac M.**, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia. *Leukemia Lymphoma* 44 (5): 791-795, 2003 .

55. Favre G, **Beksac M.**, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. *Bone Marrow Transpl* 32 (9): 873-880 Nov 2003 .

56. Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. *Blood* 102 (8): 3043-3051, Oct 2003.

57. Sanli H, Ekmekci P, Kusak F, et al.Hyperkeratosis of the nipple associated with chronic graft versus host disease after allogeneic haematopoietic cell transplantation . *Acta Derm-Venereol* 83 (5): 385-386 , 2003.

58. Kuzu I, **Beksac M.**, Arat M, Celebi C, Elhan A, Erekul S. Bone Marrow Microvessel Density (MVD) In adult Acute Myeloid Leukemia (AML): Therapy induced changes and effects on survival. *Leukemia Lymphoma* , 44(5): 791-795, 2004.

59. İlhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, **Beksac M.**, Özcan M, Gurman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. *Transfus Apheresis Sci.* 30(3):185-7, 2004.

60. İdilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. *J Viral Hepat.* 11(2):141-7, 2004.

61. Akyerli C, **Beksac M.**, Holkoc M, Frevelc M, Dalva K, Özbek U, Soydan E, Özcan M, Özet G, İlhan O, Gürman G, Akan H, Williams B, Özçelik T. Expression of IFITM1 in Chronic Myeloid Leukemia patients. *Leuk Res* 29(3):283-286,2005.

62. Schmitz N, **Beksac M.**, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, Russell N, Apperley J, Szerm J, Bradstock K, Buzyn A, Schlegelberger B, Matcham J, Gratwohl A. Filgrastim-

mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. *Haematologica.* ;90(5):643-8,2005.

63. Zwierzina H, Suciú S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, **Beksac M**, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. *Leukemia.* 2005 Nov;19(11):1929-33.

64. Bakanay SM, Dalva K, Arat M, Arslan O, Ayyildiz E, **Beksac M**, Ilhan O. Does continuous flow apheresis influence viability in allogeneic hematopoietic stem cell harvest? *Transf. Apher.Sci.* 2006 Apr;34(2):171-8. Epub 2006 Mar 20.

65. Idilman R, Kuzu I, Erden E, Arat M, Soydan E, Soykan I, Akyol G, Karayalcin S, Akan H, **Beksac M** Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation. *Bone Marrow Transplant.* 2006 Jan;37(2):199-206.

66. B G M Durie, J-L Harousseau, J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, **M Beksac**, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and S V Rajkumar on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. 2006 ,20(9):1467-73. Epub 2006 Jul 20.

67. Wu KL, **Beksac M**, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. *Haematologica.* 2006 Dec;91(12):1722-3.

68. Ali R.;**Beksac M**.;Ozkalemkas F.;Ozkocaman V.;Ozkan;Ozcelik;Tunali A. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. *Leuk Lymph* 2007; 48(7):1426-8.

69. Ludwig H, Durie B.G.M., Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, **Beksac M**, Boccadoro M, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Crowley J, Sonneveld P. Favorable prognostic features of young patients with multiple myeloma account for longer survival after conventional or high-dose therapy. *Blood* 2008 Apr 15;111(8):4039-47. Epub 2008 Feb 11.

70. Rawstron AC, Orfao A, **Beksac M**, Bezdicikova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Report of the European

Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica*. 2008 Mar;93(3):431-8.

71. **Beksaç M.**, Delforge M.,Richardson P.The evolving treatment paradigm of multiple myeloma: From past to present and future.(Sürekli gelişmekte olan bir tedavi yaklaşımı: Multipl miyeloma tedavisinin geçmişi, bugünü ve geleceği) *Turk J Hematol* 2008 ;25(2): 60-70.

72. Ozet A., Guran S., **Beksaç M.** Familial multiple myeloma associated with chronic inflammation: First report from Turkey. *Clin Lymph Myeloma*.2008;8(4):246-8.

73. Sanli H, Akay BN, Arat M, Koçyigit P, Akan H, **Beksac M**, Ilhan O.Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. *Dermatology*. 2008;216(4):349-54.

74. Brand A, Rebutta P, Engelfriet CP, Reesink HW, Beguin Y, Baudoux E, Kögler G, Ebrahimi M, Grazzini G, Costa AN, Bosi A, Sacchi N, Lombardini L, Pupella S, Lecchi L, Garcidueñas ED, van Beckhoven JM, de Wit HJ, Fibbe WE, Zhiburt EB, Bart T, **Beksaç M**, Navarrete C, Regan F. International forum: cord blood banking. *Vox Sanguinis* 2008; 95(4):335-48.

75. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, **Beksac M**, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of Multiple Myeloma. *Leukemia*. 2009 ;23(9):1545-56.

76. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. Collaborators: Alexanian R, Anderson K, Attal M, Avet-Loiseau H, Badros A, Bergsagel L, Blade J, Barlogie B, Batille R, **Beksac M**, Belch A, Bensinger B, Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Einsele H, Facon T, Fantl D, Feraud JP, Fonseca R, Gahrton G, Gertz M, Gibson J, Goldschmidt H, Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Ho J, Hungria V, Hussein M, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Kawano M, Kumar S, Kyle R, Lahuerta J, Lee JH, Lokhorst H, Ludwig H, LeLeu X, Maiolino A, Mehta J, Merlini G, Moreau P, Morgan G, Munshi N, Palumbo A, Pavlovsky S, Niesvizky R, Novis Y, Nouel A, Powles R, Pilarski L, Rajkumar SV, Reece D, Reiman T, Richardson P, Rodriguez A, Sezer O, Shaughnessy J, Shimizu K, Siegel D, Tricot G, San Miguel J, Singhal S, Sonneveld P, Shustik C, Spencer A, Stewart K, Tosi P, Turesson I, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Yehuda DB, Zonder J. *Leukemia*. 2009 Feb;23(2):215-24.

77. Shaw BE, Ball L, **Beksac M**, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. *Bone Marrow Transplant*. 2010; 45(5):832-8.
78. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, **Beksac M**, Hasenclever D, Socie G, Schmitz N. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. *Lancet Oncol*. 2010 ; 11(4):331-8.
79. Ludwig H, **Beksac M**, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist*. 2010;15(1):6-25.
80. **Beksac M**, Rıdvan A, Ozcelik T, Ozcan M, Ozcebe O, Bayık M, Paydas S, Buyukasik Y, İlhan O, Ozkalemkas F, Gurman G, Uysal A, Akan H, Akcaglayan Soydan E, Tunalı A. Short and long term effects of granulocyte colony stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. *Leuk Res* 2010 Jul 27 (epub ahead of print).
81. **Beksac M**, Haznedar R, Tuglular T, Ozdogu H, İ. Aydogdu, N. Konuk, G. Aysucak, I. Kaygusuz, S. Karakus, E. Kaya, R. Ali, Z. Gulbas, G. Ozet, H. Goker, L. Undar. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. *Eur. J. Hematol*. 2011; 86(1):16-22.
82. Attar A, Ayten M, Özdemir M, Özgencil E, Bozkurt M, Kaptanoğlu E, **Beksac M**, Kanpolat Y. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. *Cytotherapy* 2010;13:54-60.
83. MA Dimopoulos, A Palumbo, M Attal, **M Beksac**, F Davies, M Delforge, H Einsele, R Hajek, J-L Harousseau, F Leal da Costa, H Ludwig, U-H Mellqvist, G Morgan, JF San Miguel, S Zweegman, and P Sonneveld on behalf of the European Myeloma Network. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. *Leukemia*. 2011;25(5):749-60.
84. Topcuoglu P, Arat M, Ozcan M, Arslan O, İlhan O, **Beksac M**, Gurman G. Ann Hematol. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. *Ann Hematol*. 2011 ;5. [Epub ahead of print]
85. Abi-Rached L, Jobin MJ, Kulkarni S, McWhinnie A, Dalva K, Gragert L, Babrzadeh F,

Gharizadeh B, Luo M, Plummer FA, Kimani J, Carrington M, Middleton D, Rajalingam R, **Beksac M**, Marsh SG, Maiers M, Guethlein LA, Tavoularis S, Little AM, Green RE, Norman PJ, Parham P. The shaping of modern human immune systems by multiregional admixture with archaic humans. 2011 7;334(6052):89-94.

86. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hájek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, **Beksac M**, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood*. 2011 ;12 . [Epub ahead of print]

87. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orłowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, **Beksac M**, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Femand P, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczynszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orłowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken , Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. *Leukemia*. 2011; 29. doi: 10.1038/leu.2011.196.

88. Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, **Beksac M**, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol*. 2011 1;29(22):3016-22.

89. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, **Beksac M**, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I,

Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*. 2011 4;118(5):1239-47.

90. Ludwig H, **Beksac M**, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. *Oncologist*. 2011;16(4):388-403.

91. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, **Beksac M**, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*. 2011 5;117(18):4701-5.

92. **Beksac M**, Preffer F. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? *Bone Marrow Transplant*. 2011 Dec 5. doi: 10.1038/bmt.2011.240. [Epub ahead of print]

93. Richardson PG, Delforge M, **Beksac M**, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orłowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia*. 2011 Dec 23. doi: 10.1038/leu.2011.346. [Epub ahead of print]

94. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, **Beksac M**, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orłowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. *Blood*. 2012 Jan 23. [Epub ahead of print]

95. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kłoczko J, Bladé J, **Beksac M**, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*. 2012 ;366(19):1759-69.

96. Bakanay SM, Serbest E, Dalva K, Kuzu I, **Beksac M**. Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto? *Case Report Med*. 2012;2012:319530.

97. Palumbo A, Waage A, Hulin C, **Beksac M**, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M,

Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. Safety of thalidomide in newly diagnosed elderly myeloma patients: an individual patient data meta-analysis of six randomized trials. *Haematologica*. 2013 Jan;98(1):87-94.

98. **Beksac M**, Dalva K. Role of killer immunoglobulin-like receptor and ligand matching in donor selection. *Bone Marrow Res*. 2012;2012:271695.

99. Ozdemir M, Attar A, Kuzu I, Ayten M, Ozgencil E, Bozkurt M, Dalva K, Uckan D, Kılıç E, Sancak T, Kanpolat Y, **Beksac M**. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. *Stem Cell Rev*. 2012 Sep;8(3):953-62.

100. Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*. 2013 Jan 10;121(2):339-50.

101. Anghel R, Bachmann A, **Beksac M**, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Lang I, Marenca J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. *Wien Klin Wochenschr*. 2013 Aug;125(15-16):439-47.

102. Dimopoulos MA, **Beksac M**, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. *Haematologica*. 2013 Aug;98(8):1264-72.

103. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, **Beksac M**, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood*. 2013 Jun 20;121(25):5055-63.

104. Willemze R, Suci S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, **Beksac M**, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeyer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. *J Clin Oncol*.

2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2. PubMed PMID: 24297940.

105. Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, Lahuerta JJ, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel AI, Liberati AM, Cavalli M, Rossi D, Passera R, Rosso S, **Beksac M**, Cavo M, Waage A, Miguel JS, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib, Melphalan, Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in elderly newly diagnosed Multiple Myeloma patients: A retrospective case-matched study. *Am J Hematol.* 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print] PubMed PMID: 24273190.

106. Jurczynszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Diaz AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MM, Atilla E, **Beksac M**, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani S, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierzczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. *Am J Hematol.* 2016 Mar 8. doi: 10.1002/ajh.24351. [Epub ahead of print]

107. **Beksac M**, Yurdakul P. Review. How to Improve Cord Blood Engraftment? *Front Med (Lausanne).* 2016 Feb 17;3:7. doi: 10.3389/fmed.2016.00007. eCollection 2016. PMID:26925402

108. **Beksac M**. Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants? *Front Med (Lausanne).* 2016 Jan 11;2:95. doi: 10.3389/fmed.2015.00095. eCollection 2015. Review. PMID:26793711

109. Richardson PG, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. *Blood.* 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116

110. Hidayat AN, Aki-Yalcin E, **Beksac M**, Tian E, Usmani SZ, Ertan-Bolelli T, Yalcin Insight into human protease activated receptor-1 as anticancer target by molecular modelling. *I.SAR QSAR Environ Res.* 2015;26(10):795-807. doi: 10.1080/1062936X.2015.1095799. Epub 2015 Oct 26. PMID:26501801

111. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, **Beksac M**, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network guidelines for the management of multiple myeloma-related complications. *European*

112. Kalafat E, Yuce T, Konuralp B, Katlan DC, Kalaylioglu Z, **Beksac M**, Koc A, Soylemez F. Effects of in utero cord blood collection on post-cesarean hemoglobin levels. *Eur J Obstet Gynecol Reprod Biol.* 2015 Oct;193:123-6. doi: 10.1016/j.ejogrb.2015.07.022. Epub 2015 Aug 6. PMID:26295789

113. Beksac K, **Beksac M**, Dalva K, Karaagaoglu E, Tirnaksiz MB Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. *PLoS One.* 2015 Jul 16;10(7):e0132526. doi: 10.1371/journal.pone.0132526. eCollection 2015. PMID: 26181663

114. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, **Beksac M**, Alsina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. *Expert Rev Anticancer Ther.* 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: *Expert Rev Anticancer Ther.* 2015;15(9):1121. PMID:26051506

115. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, **Beksac M**, Spencer A, Oakervee H, Orłowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. PMID:26035255

116. **Beksac M**, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupporelli G, Firatlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A. Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. *Acta Haematol.* 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24. PMID: 2582429

117. Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, **Beksac M**, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. *Bone Marrow Transplant.* 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. PMID:25621805

118. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, **Beksac M**, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the

diagnosis of multiple myeloma. *Lancet Oncol.* 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.PMID: 25439696

119. Scheid C, Reece D, **Beksac M**, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. *Eur J Haematol.* 2015 Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22.PMID:25402977

120. San-Miguel JF, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol.* 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: *Lancet Oncol.* 2015 Jan;16(1):e6. PMID:25242045

121. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, **Beksac M**, Field S, Yang H, Shaw BE; World Marrow Donor Association Clinical Working Group Committee. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. *Bone Marrow Transplant.* 2014 Jul;49(7):880-6. doi: 10.1038/bmt.2014.67. Epub 2014 Apr 7.PMID:24710563

122. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, **Beksac M**, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica.* 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.PMID:24497560

123. Richardson PG, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. *Blood.* 2015 Dec 2. pii: blood-2015-09-665018. [Epub ahead of print] PubMed PMID: 26631116.

124. Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, **Beksac M**, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. *Haematologica.* 2015 Jan;100(1):100-6. doi:

10.3324/haematol.2014.112037. Epub 2014 Sep 26. PubMed PMID: 25261096; PubMed Central PMCID: PMC4281322.

125. **Beksac M**. Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?". *Front Med (Lausanne)*. 2016 May 13;3:20. doi:10.3389/fmed.2016.00020. eCollection 2016. PubMed PMID: 27243013; PubMed Central PMCID: PMC4865490.

126. Özen M, Üstün C, Öztürk B, Topçuoğlu P, Arat M, Gündüz M, Atilla E, Bolat G, Arslan Ö, Demirer T, Akan H, İlhan O, **Beksac M**, Gürman G, Özcan M. Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study. *Turk J Haematol*. 2016 Apr 18. doi: 10.4274/tjh.2015.0346. [Epub ahead of print] PubMed PMID: 27094579.

127. Özdemir NZ, Şahin U, Merter M, Gündüz M, Ateşagaoglu B, **Beksac M**. A Case of Superwarfarin Poisoning due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker. *Turk J Haematol*. 2016 Apr 18. doi: 10.4274/tjh.2015.0433. [Epub ahead of print] PubMed PMID: 27093901.

128. **Beksac M**, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P. HLA polymorphism and risk of multiple myeloma. *Leukemia*. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]

129. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, **Beksac M**, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schechter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016 Aug 25;375(8):754-66.

130. San-Miguel JF, Hungria VT, Yoon SS, **Beksac M**, Dimopoulos MA, Elghandour A, Jędrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. *Lancet Haematol*. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.

131. Raje NS, Moreau P, Terpos E, Benboubker L, Grząsko N, Holstein SA, Oriol A, Huang SY, **Beksac M**, Kuliczowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. *Br J Haematol*. 2016 Dec 22. doi:10.1111/bjh.14483. [Epub ahead of print] PubMed PMID: 28005265.

132. Gencer EB, Yurdakul P, Dalva K, **Beksac M**. Flow Cytometric Aldehyde Dehydrogenase (ALDH) Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem

CLINICAL RESEARCH EXPERIENCE

- VAD+C5A, EORTC-AML, EORTC-MDS low dose ARA-C
- Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy:
- An EORTC-German MDS Study Group Randomized Phase III Study
- The Value of High Dose Versus Standard Dose ARA-C During Induction and offL-2 After Intensive Consolidation!Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial ofthe EORTC and the GIMEMA-ALWP
- Phase III Trial of Combination Treatment with Thalidomide and Melphalan / Prednisolone for Newly Diagnosed Patients Older Than 55 Years with Multiple Myeloma who are not Candidates for High Dose Chemotherapy and Stem Cell Transplantation. Turkish Myeloma Study Group ,TMSG-OOI
- A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3 Arm Parallel-Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlinlid) in

Combination With Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older

- A randomized phase III study to compare VMP with Mel-200 followed by VRD consolidation and Lenalidomide maintenance in newly diagnosed MM patients (EMINENT study)
- A Phase III, Randomized, Open Label Trial of Lenalidomide/ Dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
- A Phase III, Randomized, Open Label Trial of Lenalidomide/ Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
- A Phase III, Randomized, Double Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
- A Phase III, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
- A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency
- A Multicenter, Randomized, Double Blind, Placebo Controlled Phase 2/3 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma
- Randomized Controlled Phase 3 Study to Evaluate Maintenance After Retreatment With Bortezomib (VELCADE) Salvage Therapy in Patient with Multiple Myeloma in First or Second Relapse (MARS)
- A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan and Prednisone versus Bortezomib, Melphalan and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma.
- A Multicenter, single arm, open label study, with pomalidomide in combination with low dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma
- A Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Subjects with Relapsed or Refractory Multiple Myeloma

- A phase 3, Multicenter, Randomized, Open Label Study to compare the efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma.
- A Phase 3, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals herpes zoster Ge/AS01B candidate vaccine when administered intramuscularly on a two dose schedule to adult autologous haematopoietic stem cell transplant recipients.
- A randomized phase 2 trial to evaluate three daratumumab dose schedules in smoldering multiple myeloma.
- A phase3, randomized, placebo-controlled,double-blind study of oral ixazomib maintenance therapy after initial therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplantation.
- A phase 3, Randomized, Controlled,Open-label study of velcade melphalan-prednisone (VMP) Compared to Daratumumab in combination with VMP in subjects with previously untreated multiple myeloma who are ineligible for high -dose therapy.

